Arnd Jacobi

Summary

Country: Germany

Publications

  1. ncbi request reprint Infliximab in the treatment of moderate to severe atopic dermatitis
    Arnd Jacobi
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Am Acad Dermatol 52:522-6. 2005
  2. doi request reprint Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study
    Arnd Jacobi
    Department of Dermatology, University Hospital Marburg, Marburg, Germany
    Dermatology 216:133-6. 2008
  3. ncbi request reprint [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]
    Arnd Jacobi
    Dermatologische Klinik mit Poliklinik der Universität Erlangen Nürnberg
    J Dtsch Dermatol Ges 1:259-72. 2003

Detail Information

Publications3

  1. ncbi request reprint Infliximab in the treatment of moderate to severe atopic dermatitis
    Arnd Jacobi
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Am Acad Dermatol 52:522-6. 2005
    ..Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable efficacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of tumor necrosis factor-alpha, may be a novel option...
  2. doi request reprint Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study
    Arnd Jacobi
    Department of Dermatology, University Hospital Marburg, Marburg, Germany
    Dermatology 216:133-6. 2008
    ..Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis...
  3. ncbi request reprint [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]
    Arnd Jacobi
    Dermatologische Klinik mit Poliklinik der Universität Erlangen Nürnberg
    J Dtsch Dermatol Ges 1:259-72. 2003
    ....